NeuroBo Pharmaceuticals Inc (NRBO)

Overview News Price History Discussions Forecast Stock Split

NeuroBo Pharmaceuticals Inc stock is currently priced at $3.0799, with a 24-hour trading volume of 40,196. It has seen a -1.29% decreased in the last 24 hours and a -30.94% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $3.17 pivot point. If it approaches the $3.03 support level, significant changes may occur.

NeuroBo Pharmaceuticals Inc Stock (NRBO) Financials Data

NeuroBo Pharmaceuticals Inc (NRBO) Net Income 2024

NRBO net income (TTM) was -$12.47 million for the quarter ending December 31, 2023, a +10.72% increase year-over-year.

NeuroBo Pharmaceuticals Inc (NRBO) Cash Flow 2024

NRBO recorded a free cash flow (TTM) of -$10.85 million for the quarter ending December 31, 2023, a +7.37% increase year-over-year.

NeuroBo Pharmaceuticals Inc (NRBO) Earnings per Share 2024

NRBO earnings per share (TTM) was -$2.38 for the quarter ending December 31, 2023, a +97.20% growth year-over-year.

NeuroBo Pharmaceuticals Inc Stock (NRBO) Latest News

Dow Jumps 250 Points; Honeywell Issues Weak Forecast

Benzinga

Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Crude Oil Gains 1%; ISM Manufacturing PMI Tops Expectations

Benzinga

Nasdaq Surges 100 Points; US Jobless Claims Increase To 224,000

Benzinga

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.